This site is intended for health professionals only

Colon cancer drug “boosts survival”

teaser

A colon cancer drug has boosted overall survival in heavily pre-treated patients with advanced metastatic colon cancer, it has been claimed.

Patients receiving the drug KRX-0401, or perifosine, showed more than 60% improvement in overall survival and showed statistically significant advantage for time to progression, when compared with a dummy drug, said Keryx Biopharmaceuticals.

But the patients who were on the drug showed a greater incidence of adverse events such as anaemia and hand-foot syndrome compared with those on the dummy, the company said in a statement.

A total of 38 patients in the study were either given the drug in combination with the chemotherapy treatment capecitabine, or were just given capecitabine in combination with a dummy drug.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Perifosine is now being tested in another late-stage trial for the treatment of relapsed/refractory multiple myeloma.

Ron Bentsur, chief executive of the company, said in the statement: “We are eager to finalize the design of a Phase 3 protocol in metastatic colorectal cancer within the next three months, in consultation with the FDA, and to commence the Phase 3 study as soon as practicable.”

Copyright Press Association 2010

Department of Health






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x